(Q33418555)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

0 references

1 reference

title

Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

main subject

angiogenesis inhibitor

1 reference

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Shaodong Hong

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Min Tan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Shouzheng Wang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Yue Chen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Li Zhang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

6 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cancer Research and Clinical Oncology

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

909-921

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25373315%20AND%20SRC:MED&resulttype=core&format=json

Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and Sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Tumor angiogenesis and anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Targeted therapies for non-small cell lung cancer: an evolving landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Current status of targeted therapy in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Angiogenic growth factors and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

21 January 2018

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Current treatments for advanced stage non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Angiogenesis and tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1862-5

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer.

21 January 2018

1 reference

12 December 2020

The use of bevacizumab in non-small cell lung cancer: an update

1 reference

12 December 2020

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study

1 reference

12 December 2020

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)

1 reference

12 December 2020

Emerging targeted therapies in metastatic renal cell carcinoma.

1 reference

12 December 2020

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial

1 reference

12 December 2020

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy

1 reference

12 December 2020